Lack of activated Smad2 in transforming growth factor-β signaling is an unfavorable prognostic factor in patients with esophageal squamous cell carcinoma

Journal of Surgical Oncology

Volumn 94, Issue 1, 2006, Pages 51-56

  Fukuchi, Minoru ^a   Nakajima, Masanobu ^a   Miyazaki, Tatsuya ^a   Masuda, Norihiro ^a   Osawa, Hidenobu ^a   Manda, Ryokuhei ^a   Tsukada, Katsuhiko ^a   Kato, Hiroyuki ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Activated Smad2; Esophageal squamous cell carcinoma; Immunohistochemistry; Smad2; Smad3; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; ESOPHAGUS CARCINOMA; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA;

EID: 33745661630     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20565     Document Type: Article

References (29)

1. Robert AB, Sporn MB: The transforming growth factor-βs. In: Robert AB, Sporn MB, editors. Peptide growth factors and their receptors, part, Vol. 95, Heidelberg, Germany: Springer-Verlag; 1990; 419-472.
2. Heldin CH, Miyazono K, ten Dijke P: TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
3. Massagué J, Wotton D: Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000;19:1745-1754.
4. Miyazono K, ten Dijke P, Heldin CH: TGF-β signaling by Smad proteins. Adv Immunol 2000;75:115-1157.
5. Attisano L, Wrana JL: Smads as co-modulators. Curr Opin Cell Biol 2000;12:235-243.
6. Miyazono K: Positive and negative regulation of TGF-β signaling. J Cell Sci 2000;113:1101-1109.
7. Lahm H, Odartchenko N: Role of transforming growth factor β in colorectal cancer. Growth factor 1993;9:1-9.
8. White RL: Tumor suppressing pathways. Cell 1998;92:591-592.
9. Markowitz SD, Roberts AB: Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102.
10. Zhang Y, Musci T, Derynck R: The tumor suppressor Smad4/DPC4 as a central mediator of Smad function. Curr Biol 1997;7:270-276.
11. Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at chromosome 18q21.1. Science 1996;271:350-353.
12. Takagi Y, Kohmura H, Futamura M, et al.: Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996;111:1369-1372.
13. Nagatake M, Takagi Y, Osada H, et al.: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancer. Cancer Res 1996;56:2718-2720.
14. Tamura G, Sakata K, Nishizuka S, et al.: Allelotype of adenoma and differentiated adenocarcinoma of the stomach. J Pathol 1996;180:371-377.
15. Schutte M, Hruban RH, Hedrick L, et al.: DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
16. Eppert K, Scherer SW, Ozcelik H, et al.: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.
17. Takenoshita S, Mogi A, Nagashima M, et al.: Characterization of the MADH2/Smad2 gene, a human Mad homologue responsible for the transforming growth factor-β and activin signal transduction pathway. Genomics 1998;48:1-11.
18. Riggns GJ, Kinzler KW, Vogelstein B, et al.: Frequency of Smad gene mutations in human cancers. Cancer Res 1997;57:2578-2580.
19. Osawa H, Shitara Y, Shoji H, et al.: Mutation analysis of transforming growth factor βtype II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma. Int J Oncol 2000;17:723-738.
20. Fukuchi M, Masuda N, Miyazak T, et al.: Decreased Smad4 expression in the transforming growth factor-β signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 2002;95:737-743.
21. Prunier C, Ferrand N, Frottier B, et al.: Mechanism for mutational inactivation of the tumor suppressor Smad2. Mol Cell Biol 2001;21:3302-3313.
22. Ink4B transcription in response to TGF-β. EMBO J 2000;19:5178-5193.
23. Korchynskyi O, Landstrom M, Stoika R, et al.: Expression of Smad proteins in human colorectal cancer. Int J Cancer 1999;82:197-202.
24. Muro-Cacho CA, Rosario-Ortiz K, Livingston S, et al.: Defective transforming growth factor-β signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2. Clin Cancer Res 2001;7:1618-1626.
25. Kuwano H, Saeki H, Kawaguchi H, et al: Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous-cell carcinoma. Int J Cancer 1998;78:149-152.
26. Inagaki Y, Mamura M, Kanamaru Y, et al.: Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 2001;187:117-123.
27. Lin X, Liang M, Feng XH: Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 2000;275:36818-36822.
28. Yagi K, Goto D, Hamamoto T, et al.: Alternatively spliced variant of Smad2 lacking exon3. J Biol Chem 1999;274:703-709.
29. Akiyoshi S, Inoue H, Hanai J, et al.: c-Ski acts a transcriptional co-repressor in transforming growth factor β signaling through interaction with Smads. J Biol Chem 1999;274:35269-35277.